Metropolitan Life Insurance Company (MetLife)’s Atea Pharmaceuticals AVIR Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio AVIR Stock Details AVIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-2,613	Closed	-$10.6K	–	217
2024 Q1	$10.6K	Buy	2,613 +416	+19%	+$1.63K	﹤0.01%	2120
2023 Q4	$6.7K	Sell	2,197 -2,381	-52%	-$7.21K	﹤0.01%	2267
2023 Q3	$13.7K	Hold	4,578	–	–	﹤0.01%	2071
2023 Q2	$17.1K	Buy	+4,578	New	+$17.1K	﹤0.01%	2014
2023 Q1	–	Sell	-4,928	Closed	-$23.7K	–	2325
2022 Q4	$23.7K	Hold	4,928	–	–	﹤0.01%	1920
2022 Q3	$28K	Hold	4,928	–	–	﹤0.01%	1830
2022 Q2	$35K	Hold	4,928	–	–	﹤0.01%	1719
2022 Q1	$35.6K	Sell	4,928 -13,943	-74%	-$94.7K	﹤0.01%	1783
2021 Q4	$169K	Hold	18,871	–	–	﹤0.01%	2143
2021 Q3	$662K	Buy	+18,871	New	+$523K	0.01%	1261
2021 Q2	–	Sell	-4,621	Closed	-$285K	–	2725
2021 Q1	$285K	Sell	4,621 -226	-5%	-$15.3K	﹤0.01%	1777
2020 Q4	$203K	Buy	+4,847	New	+$156K	﹤0.01%	1928

Other funds holding AVIR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s AVIR Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Atea Pharmaceuticals (AVIR) in Q2 2024, closing a stake of 2,613 shares — an estimated $10.6K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in AVIR in Q4 2020 and held it in 12 quarters. The position peaked at $662K in Q3 2021. 105 funds tracked by Wall St. Rank hold AVIR as of Q2 2024.

Metropolitan Life Insurance Company (MetLife) reported no remaining Atea Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 2,613 Atea Pharmaceuticals shares in Q2 2024, an estimated $10.6K.
Metropolitan Life Insurance Company (MetLife) first reported a position in Atea Pharmaceuticals in Q4 2020 and held it in 12 quarters.
Metropolitan Life Insurance Company (MetLife)'s Atea Pharmaceuticals position peaked at $662K in Q3 2021.
105 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.